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Abstract—The literature shows inconsistent evidence regard-
ing the association between clinically assessed plantarflexor 
(PF) spasticity and walking function in ambulatory persons 
with multiple sclerosis (pwMS). The use of a dynamometer-
based spasticity measure (DSM) may help to clarify this asso-
ciation. Our cohort included 42 pwMS (27 female, 15 male; 
age: 42.9 +/– 10.2 yr) with mild clinical disability (Expanded 
Disability Status Scale score: 3.6 +/– 1.6). PF spasticity was 
assessed using a clinical measure, the modified Ashworth 
Scale (MAS), and an instrumented measure, the DSM. Walk-
ing function was assessed by the timed 25-foot walk test 
(T25FWT), the 6-minute walk test (6MWT), and the 12-item 
Multiple Sclerosis Walking Scale (MSWS-12). Spearman rho 
correlations were used to evaluate relationships between spas-
ticity measures, measures of walking speed and endurance, and 
self-perceived limitations in walking. The correlation was 
small between PF spasticity and the T25FWT (PF maximum 
[Max] MAS rho = 0.27, PF Max DSM rho = 0.26), the 6MWT 
(PF Max MAS rho = 0.20, PF Max DSM rho = 0.21), and 
the MSWS-12 (PF Max MAS rho = 0.11, PF Max DSM rho = 
0.26). Our results are similar to reports in other neurologic 
clinical populations, wherein spasticity has a limited associa-
tion with walking dysfunction.
Key words: 12-item Multiple Sclerosis Walking Scale, ambula-
tion, dynamometer, modified Ashworth Scale, multiple sclero-
sis, self-perceived limitations, spasticity, walking dysfunction, 
walking endurance, walking speed.
INTRODUCTION
Multiple sclerosis (MS) is a chronic, inflammatory 
disease of the central nervous system (CNS) character-
ized by demyelination and loss of motor and sensory 
axons within the brain and spinal cord [1]. Spasticity, 
defined as a motor disorder characterized by a velocity-
dependent increase in tonic stretch reflexes and increased 
tendon jerks resulting from disinhibition of the stretch 
reflex [2], is a typical consequence of pathological 
changes within the corticospinal system. Lower-limb 
spasticity is believed to be a key contributor to mobility 
disability in persons with MS (pwMS). As such, lower-
limb spasticity is routinely assessed in clinical practice to 
Abbreviations: 6MWT = 6-minute walk test, CNS = central 
nervous system, DF = dorsiflexion, DSM = dynamometer-
based spasticity measure, EDSS = Expanded Disability Status 
Scale, EMG = electromyography, MAS = modified Ashworth 
Scale, Max = maximum, MS = multiple sclerosis, MSWS-12 = 
12-item Multiple Sclerosis Walking Scale, PF = plantarflexor, 
pwMS = persons with multiple sclerosis, ROM = range of 
motion, RRMS = relapsing-remitting multiple sclerosis, 
T25FWT = timed 25-foot walk test.
*Address all correspondence to Joanne M. Wagner, PT, 
PhD; Program in Physical Therapy, 3437 Caroline Mall, 
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document clinical disability and monitor disease progres-
sion, and therapies aimed at reducing spasticity are 
employed to promote better walking in pwMS [3–4].
PwMS perceive spasticity to be related to self-
reported mobility disability [5]. Nonetheless, there is 
inconsistent evidence regarding the association between 
lower-limb spasticity, measured using the modified Ash-
worth Scale (MAS) [6], and walking speed, walking 
endurance, and self-perceived walking limitations. Sos-
noff et al. reported on a group of 34 pwMS, 15 of whom 
exhibited plantarflexor (PF) spasticity [7]. In this cohort 
of pwMS, the group with PF spasticity had slower walk-
ing speed (p = 0.02), reduced walking endurance (p < 
0.01), and greater self-perceived walking limitations (p = 
0.04) than the group without spasticity. In contrast, we 
recently reported a small relationship between PF spas-
ticity measured using the MAS and walking speed (ρ = 
0.27, p = 0.08), walking endurance (ρ = 0.20, p = 0.20), 
and self-perceived walking limitations (ρ = 0.11, p = 
0.48) [8]. There also were no differences in walking 
speed (p = 0.34), walking endurance (p = 0.72), or self-
perceived walking limitations (p = 0.64) in pwMS with 
PF MAS scores greater than 0 (n = 29) compared with 
pwMS with PF MAS equal to 0 (n = 13).
The MAS is the most commonly reported clinical 
measure of spasticity; however, the objectivity of the 
MAS has been questioned [9]. Dynamometer-based spas-
ticity measures (DSMs), which objectively quantify 
velocity-dependent resistance to passive movement, have 
been developed to address the subjectivity of the MAS 
[10–14]. Dynamometer-based estimates of lower-limb 
spasticity have confirmed a limited association between 
lower-limb spasticity, as measured using clinical scales, 
and walking dysfunction in other neurologic clinical pop-
ulations [10–14]. Quantifying spasticity using a DSM in 
addition to the MAS may clarify the ambiguous evidence 
regarding the effect of lower-limb spasticity on walking 
dysfunction in pwMS. A better understanding of the asso-
ciation between lower-limb spasticity and walking dys-
function in pwMS is required for the development of 
targeted therapeutic interventions aimed at improving 
walking.
The purpose of this study was to determine the effect 
of PF spasticity on walking function in pwMS by exam-
ining the relationships between clinically assessed PF 
spasticity; a DSM of PF spasticity; and walking function 
assessed by standardized measures of walking speed, 
walking endurance, and self-perceived walking limita-
tions. We hypothesized based on our previous work in 
this cohort [8], and based on studies of walking dysfunc-
tion in people with other CNS conditions, that there is a 
limited association between PF spasticity, whether mea-
sured clinically or using a dynamometer, and walking 




Study participants included 45 ambulatory pwMS. 
All participants were recruited through the Multiple Scle-
rosis Clinic at Saint Louis University, The John L. Trotter 
Multiple Sclerosis Clinic at Washington University 
School of Medicine, and the Gateway chapter of the 
National Multiple Sclerosis Society. Participants were 
included (1) if they had a diagnosis of MS from a board-
certified neurologist, including relapsing-remitting MS 
(RRMS), secondary progressive MS, and primary pro-
gressive MS; (2) if they were 18 to 65 yr old; (3) if they 
had minimal to moderate clinical disability as evidenced 
by an Expanded Disability Status Scale (EDSS) score 
ranging from 0.0 to 6.0, as determined by a board-
certified neurologist; and (4) if they had RRMS but were 
at least 6 mo following their last clinical exacerbation of 
MS. Participants were excluded if they (1) had lower-
limb orthopedic conditions that limited ambulation, 
(2) were pregnant, or (3) were unable to provide 
informed consent.
Data Collection
PF spasticity was measured bilaterally using the MAS 
[6]. The MAS provides a rating of spasticity on a 0 to 4 
scale, where 0 = no increase in muscle tone and 4 = 
affected part(s) are rigid in flexion or extension. The MAS 
has been found to be a reliable measure in pwMS [15].
Walking function was assessed by standardized mea-
sures of walking speed, walking endurance, and self-per-
ceived walking limitations. The timed 25-foot walk test 
(T25FWT), a component of the Multiple Sclerosis Func-
tional Composite, is a standardized clinical measure of 
short-distance maximal walking speed [16]. The 6-minute 
walk test (6MWT) is a standardized clinical measure of 
walking endurance [17]. The 12-item Multiple Sclerosis 
Walking Scale (MSWS-12) is a self-report measure of the 
effect of MS on walking ability [18]. The MSWS-12 
977
KREMER et al. Dynamometer-based PF spasticity in MS
provides a score from 0 to 100, with larger values indicat-
ing a greater perception of walking difficulty due to MS. 
These tests were administered following standardized pro-
cedures by a physical therapist.
PF spasticity was also quantified using a Biodex Sys-
tem 4 dynamometer (Biodex Medical Systems, Inc; Shir-
ley, New York). Both ankles were tested in a random 
order. Each participant was placed on the dynamometer 
in a semisupine position. For the tested limb, the leg was 
positioned so that the knee was in full extension and sup-
ported by the dynamometer chair. The foot was placed 
in the dynamometer dorsiflexion (DF)/plantar flexion 
attachment, and the ankle joint center was aligned with 
the center of rotation of the dynamometer. All partici-
pants were tested wearing shoes. Ankle range of motion 
(ROM) limits were preestablished to allow for a total of 
40 of ROM, ranging from 30 PF to 10 DF. Waist and 
knee straps were used to stabilize the pelvis and lower 
limb, and a foot rest provided support for the nontested 
limb. For the test, the ankle was passively rotated from 
PF to DF 3 times at an angular velocity of 5 °/s and 10 
times at angular velocities of 20, 60, and 90 °/s [19]. Par-
ticipants were instructed not to help move the lever arm 
and remain relaxed while spasticity measurements were 
being taken. DSMs have moderate reliability [10,12]. 
Bipolar surface electromyography (EMG) electrodes 
(MA300 EMG system, Motion Lab Systems Inc; Baton 
Rouge, Louisiana) placed on the gastroc-soleus and ante-
rior tibialis were used to visually monitor agonist and 
antagonist muscle activity, respectively, to ensure the 
movement was passive. Analog torque (foot-pounds), 
position (degrees), and velocity (degrees per second) sig-
nals were sampled directly from the dynamometer at a 
rate of 1 kHz using a PowerLab 16/30 (ADInstruments; 
Dunedin, New Zealand) and LabChart Pro version 7 soft-
ware (ADInstruments) and saved directly to disk for sub-
sequent analysis.
Data Analysis
Because the MAS includes a score of 1+, the raw PF 
MAS scores were transformed to a 0 to 5 scale [20]. The 
PF maximum (Max) MAS score (PF Max MAS) for each 
participant was determined and used for subsequent analy-
sis. PwMS with PF MAS scores 1.0 or more for either leg 
were classified as having spasticity, whereas pwMS with 
PF MAS scores less than 1.0 on both legs were classified 
as not having spasticity [7].
For the DSM, data analysis was performed using 
LabChart Pro version 7 and MATLAB R2011b (The 
MathWorks Inc; Natick, Massachusetts). Torque angle 
data were low-pass filtered (50 Hz) then processed to 
correct for the effects of limb weight and gravity using an 
anthropomorphic method [21]. The weight of the foot 
was assumed to be 1.45 percent of the entire body weight 
[22]. The first trial of each velocity was excluded from 
analyses. To determine the average resistance to stretch 
for an entire trial, the work done on the dynamometer 
was calculated by determining the area under the gravity-
corrected torque versus angle curve. To exclude end 
effects caused by the dynamometer, the boundaries of the 
area were set at 5, 30, the torque curve, and the zero 
torque line. Work can be calculated using the formula 
Equation 1:
,                                   (1)
where T = the torque produced
Figure 1.
Work was calculated by determining area between gravity-
corrected torque versus angle curve and zero torque. To 
exclude end effects, boundaries of area were set at 5, 30, 
torque curve, and zero torque line. Work can be calculated 
using the equation, where T = torque produced against dyna-
mometer and dθ = small change in angle.
 against the dynamometer 
and dθ = a small change in the angle (Figure 1) [10]. The 
30
5
T d   
Figure 2.
Raw data for person with multiple sclerosis (a) with clinically assessed spasticity (plantarflexor modified Ashworth Scale [PF MAS] = 
3) at different velocities, (b) with associated regression line of best fit, (c) with raw data without spasticity (PF MAS = 0) at different 
velocities, and (d) with associated regression line of best fit.
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average work was calculated for each individual at each 
velocity tested. Linear regression was used to determine 
the slope of the line of best fit for the average work as a 
function of velocity (Figure 2). This slope has been 
shown to be a quantitative measure of spasticity in that it 
represents a velocity-dependent resistance to passive 
stretch [10]. The maximum slope value calculated for 
each participant was used for subsequent analysis (PF 
Max DSM).
Statistical Analysis
Statistical analyses were performed in SPSS version 
20 (IBM Corporation; Armonk, New York). Significance 
was accepted at p < 0.05. Since distributions were not nor-
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mal, Spearman rho correlations were used to evaluate rela-
tionships between spasticity measures (PF Max MAS, PF 
Max DSM) and measures of walking speed (T25FWT), 
walking endurance (6MWT), and self-perceived 
limitations in walking (MSWS-12). Interpretation of the 
magnitude of the correlation coefficients were as follows: 
weak (r < 0.30), moderate (0.30  r < 0.70), and strong 
(r  0.70) [23]. Based on our sample size, correlation 
coefficients greater than 0.30 and 0.49 were statistically 
significant at the p < 0.05 and p < 0.001 levels, 
respectively [24]. Mann-Whitney U tests assessed differ-
ences in DSM between pwMS with a MAS  1 and pwMS 
with a MAS = 0. The magnitude of the difference between 
groups (pwMS with a MAS  1 vs pwMS with a 
MAS = 0) was estimated by calculating the Cohen d effect 
size [25].
RESULTS
Three participants were excluded from data analysis 
because their dynamometer data could not be processed: 
one participant due to an extremely limited DF ROM and 
two participants because the ankle was unable to be pas-
sively rotated due to ankle clonus or leg spasms confirmed 
by visual inspection of EMG. Table 1 provides demo-
graphics and clinical characteristics of the remaining 
participants (n = 42). Based on median EDSS scores, our 
sample of pwMS had mild clinical disability [26]. Of the 
participants, 12 (29%) reported using a straight cane for 
community ambulation. Seven (17%) pwMS used a cane 
during the T25FWT. Nine (21%) pwMS used a cane dur-
ing the 6MWT. Three of these participants wore a unilat-
eral ankle-foot orthosis during testing. Six (14%) pwMS 
reported the use of oral antispasticity medications.
Our sample of pwMS had mild PF spasticity based 
on the PF Max MAS and PF Max DSM values (Table 2) 
[27]. Of the participants, 69 percent (29/42) were classi-
fied as having clinically assessed spasticity based on a PF 
MAS score  1 on either leg. The PF Max MAS and the 
PF Max DSM were measured in the same limb in 90 per-
cent (38/42) of participants. PF Max DSM values did not 
differ between pwMS with a MAS  1 and pwMS with a 
MAS = 0 (0.0040 ± 0.0015 vs 0.0037 ± 0.0012, p = 0.38, 
d = 0.23). There was a weak relationship between the 
clinically assessed measures and DSMs of PF spasticity 
(PF Max MAS vs
Variable Value
Participants (n) 42
Age (yr), mean ± SD (range) 42.9 ± 10.2 (24–63)
BMI, mean ± SD (range) 26.7 ± 5.4 (20.4–42.7)




EDSS, median (IQR) [range] 3.0 (2.9–4.8) [0–6]




Time Since Diagnosis (yr),
mean ± SD (range)
7.7 ± 6.1 (1–20)
 PF Max DSM: ρ = 0.260, p = 0.10).
Our sample of pwMS had mild to moderate limitations 
in walking speed and endurance [17,28] and self-perceived 
limitations in walking (Table 2). Regardless of the 
method, PF spasticity weakly correlated with the T25FWT 
(PF Max MAS: ρ = 0.27, p = 0.08; PF Max DSM: ρ = 
0.26, p = 0.10), 6MWT (PF Max MAS: ρ = 0.20, p = 
0.20; PF Max DSM: ρ = 0.21, p = 0.18), and MSWS12 
(PF Max MAS: ρ = 0.11, p = 0.48; PF Max DSM: ρ = 0.26, 
p = 0.09).
DISCUSSION
The major finding of this study is that PF spasticity 
has a limited association with walking speed, walking 
endurance, and self-perceived walking limitations in 
pwMS with mild clinical disability, regardless of whether 
spasticity was measured clinically or using a dynamome-
ter. The DSM confirmed our previous report of a weak 
association between clinically assessed PF spasticity and 
walking dysfunction in this cohort of pwMS [8]. Our 
results are consistent with reports in other neurologic clini-
cal populations, wherein spasticity quantified with clinical 
scales or instrumented measures has a limited association 
with walking dysfunction [29–32]. The poor association 
found between PF spasticity and walking dysfunction may 
help explain the limited efficacy of spasticity management 
for improving walking in pwMS [33–34], at least in pwMS 








BMI = body mass index, EDSS = Expanded Disability Status Scale, IQR = 
interquartile range, MS = multiple sclerosis, PP = primary progressive, RR = 
relapsing-remitting, SD = standard deviation, SP = secondary progressive.
Measure Mean Standard Deviation Range
PF Max MAS (score) 1.43 1.33 0–4
PF Max DSM (J/[/s]) 0.0039 0.0014 0.0022–0.0096
T25FWT (s) 5.84 2.30 3.68–14.8
6MWT (m) 466.7 133.9 157.9–677.0
MSWS-12 (score) 42.9 22.3 0–90.5
Median Interquartile Range Range
PF Max MAS (score) 1 0–2 0–4
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Self-reported walking difficulties become more com-
mon and more pronounced in pwMS as the severity of 
self-reported spasticity increases [5,35]. It is possible that 
the weak association found between PF spasticity and 
self-reported walking dysfunction in our cohort of pwMS 
is due to the low levels of spasticity in our cohort of 
pwMS. A stronger association might exist between PF 
spasticity, quantified using the MAS or DSM, and self-
reported walking dysfunction in pwMS with more severe 
PF spasticity or in pwMS exhibiting clonus.
Our results differ from a report on pwMS where 
those with PF spasticity were found to have greater 
mobility impairment than those without PF spasticity [7]. 
In Sosnoff et al., the spasticity group had considerably 
greater clinical disability than the no spasticity group [7]. 
The association between PF spasticity and mobility 
impairment was not reported. In our cohort, clinical dis-
ability was similar between the spasticity and no spastic-
ity groups. We have previously reported no differences in 
walking between the groups [8]. Because the level of PF 
spasticity was similar in both studies, it is possible that 
additional impairments contributing to overall disability 
(i.e., weakness, sensory loss, and ataxia) may have con-
tributed to the group differences in mobility reported by 
Sosnoff et al. [7].
The weak association between the MAS and DSM in 
our cohort of ambulatory pwMS is congruent with 
reports in other neurologic clinical populations, demon-
strating a limited association between clinical and instru-
mented measures of upper- and lower-limb spasticity 
[10,13–14,36]. Collectively, these results suggest that the 
MAS and DSM may quantify different components of 
spasticity. The MAS quantifies “increase in muscle 
tone,” which may be due to both reflex and nonreflex 
components of resistance to passive movement [6]. The 
DSM quantifies the change in work at different veloci-
ties. The nonreflex component (e.g., stiffness) of resis-
tance to passive movement should be similar at different 
velocities. Therefore, we believe the DSM primarily 
quantifies the reflex component of resistance to passive 
stretch. Our study design does not allow us to determine 
the unique contribution of the nonreflex component of 
spasticity [37]. Differences in participant positioning for 
the two measures may also contribute to the weak associ-
ation between clinical and instrumented measures. Addi-
tionally, the limited range of MAS scores in our cohort of 
ambulatory pwMS may have attenuated the relationship 
between the MAS and DSM [14].
The median MAS score for the spasticity group was 
slightly larger than the median MAS score for the no 
spasticity group. Consistent with the MAS, the average 
DSM value for pwMS with clinically assessed PF spas-
ticity was slightly larger than the value for pwMS with-
out clinically assessed PF spasticity. The DSM values for 
pwMS with a MAS  1 and pwMS with a MAS = 0 were 
similar to the PF DSM value reported for children with-
out disability [8]. Thus, the DSM confirmed the mild 
severity of clinically assessed PF spasticity in our cohort 
of ambulatory pwMS with mild disability.
The current study has limitations. First, pwMS in this 
investigation had low levels of clinical spasticity; there-
fore, the results may not generalize to ambulatory pwMS 
with more pronounced clinical spasticity. Second, pwMS 
exhibiting clonus or muscle spasms during the DSM 
were excluded from analyses because it invalidated our 
algorithm for processing velocity-dependent resistance to 
passive stretch. Third, the ROM during the DSM was 
truncated due to the deceleration artifact of the dyna-
mometer. Thus, the DSM did not evaluate spasticity over 
the entire ROM. Fourth, because reflexes depend on the 
Table 2.
Spasticity and walking measures for persons with multiple sclerosis (n = 42).
6MWT = 6-minute walk test, DSM = dynamometer-based spasticity measure, MAS = modified Ashworth Scale, Max = maximum, MSWS-12 = 12-item Multiple 
Sclerosis Walking Scale, PF = plantarflexor, T25FWT = timed 25-foot walk test.
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specific task and limb positioning [38], spasticity mea-
sured in the semisupine position may not be equivalent to 
spasticity measured during ambulation. Fifth, spasticity 
was only evaluated at the ankle; we are unable to deter-
mine whether, and to what extent, spasticity of other 
muscle groups contribute to walking dysfunction in 
pwMS. Finally, our study was not designed to investigate 
the contribution of other lower-limb impairments to 
walking dysfunction.
CONCLUSIONS
PF spasticity has a limited association with walking 
speed, walking endurance, and self-perceived walking 
limitations in pwMS with mild clinical disability, regard-
less of whether spasticity was measured clinically using 
the MAS or using a dynamometer. The weak association 
between the DSM and the MAS suggests that the two 
tests may quantify different components of spasticity.
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